Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.51 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.51 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | GJA1 | P17302 | 1/20 | 0.50 |
| ▸ | GJB2 | P29033 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18197649 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL4257808 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL12694649 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL17154856 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL25304700 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL20111150 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL23029503 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL20063941 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL5357747 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL5081689 | 1.00 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791069-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8663599-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8461316-B1 | Nanoparticles for delivery of bioactive agents | GP MEDICAL, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8337811-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8318200-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8287905-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120258176-A1 | NANOPARTICLES FOR PROTEIN DRUG DELIVERY | NANOMEGA MEDICAL CORPORATION | 2012-10-11 | — | — | US | disclosed |
| US-8283317-B1 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8257740-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120207845-A1 | PHARMACEUTICAL COMPOSITION OF NANOPARTICLES | NANOMEGA MEDICAL CORPORATION | 2012-08-16 | — | — | US | disclosed |
| US-7863258-B1 | positively charged chitosan shell, polyglutamic acid core, negative surface charge; enhanced permeability for paracellular drug delivery; pemetrexed; gemcitabine | GP MEDICAL, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7858596-B2 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7611690-B2 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7604795-B1 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090202628-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2009-08-13 | — | — | US | disclosed |
| US-7556826-B2 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090155374-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090142405-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-7541046-B1 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090004266-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207845-A1 | PHARMACEUTICAL COMPOSITION OF NANOPARTICLES | DSP, EPCAM, JUP | MEN1 925/4885KMT2A 3550/4885PTPN1 875/4885 |
| US-20120258176-A1 | NANOPARTICLES FOR PROTEIN DRUG DELIVERY | PELP1, ARGLU1, ACP1 | MEN1 2726/4885KMT2A 3305/4885PTPN1 2096/4885 |
| US-20090142405-A1 | Nanoparticles for protein drug delivery | SLC47A1, LNPEP, SLC1A5 | MEN1 3843/4885KMT2A 4186/4885PTPN1 3366/4885 |
| US-20090004266-A1 | Nanoparticles for protein drug delivery | PELP1, FABP2, BMP6 | MEN1 3731/4885KMT2A 4091/4885PTPN1 3880/4885 |
| US-20090202628-A1 | Nanoparticles for protein drug delivery | SLC47A1, LNPEP, SLC1A5 | MEN1 3843/4885KMT2A 4186/4885PTPN1 3366/4885 |
| US-20090155374-A1 | Nanoparticles for protein drug delivery | SLC47A1, LNPEP, SLC1A5 | MEN1 3843/4885KMT2A 4186/4885PTPN1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.